Wanbury Limited Schedules Board Meeting on 4th Nov'26 for Q2 Financial Results
Wanbury Ltd 路 Intimation 路 04 Nov 2026, 5:30 am
Wanbury Limited Schedules Board Meeting on 4th Nov'26 for Q2 Financial Results Wanbury Limited announced that a meeting of its Board of Directors is scheduled for 4th Nov'26 to consider and approve the standalone and consolidated un-audited financial results for the second quarter and half year ended 30th Sep'26. In accordance with SEBI insider trading regulations, the trading window for dealing in company securities remains closed for designated persons and key managerial personnel until 48 hours after the declaration of the financial results.
Original exchange filing (PDF)
More announcements from Wanbury Ltd
- Disclosure under Regulation 30 of the SEBI LODR, 2015 - Investors Presentation on Q2 and Half Year ended 30.09.2026. 路 18 Nov 2026
- Clarifications on investor queries regarding recent announcement 路 16 Nov 2026
- Wanbury Limited''s Tanuku Plant - US FDA Inspection - Updates 路 16 Nov 2026
- Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HC1 EP grade. 路 12 Nov 2026
- Press Release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026. 路 06 Nov 2026
- Financial Results as on 30th September, 2026 路 05 Nov 2026
- Outcome of the Board Meeting held on November 04, 2026 路 05 Nov 2026
- Wanbury Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
